Results overview: Found 3 records in 0.04 seconds.
Articles, 3 records found
Articles 3 records found  
1.
12 p, 1.7 MB Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer / Kirschbrown, Whitney. P. (Clinical Pharmacology. Genentech Research and Early Development) ; Wang, B. (Clinical Pharmacology. Genentech Research and Early Development) ; Nijem, I. (Clinical Pharmacology. Genentech Research and Early Development) ; Ohtsu, A. (Department of Gastrointestinal Oncology. National Cancer Center Hospital East) ; Hoff, P. M. (Instituto do Câncer de São Paulo. Faculdade de Medicina da Universidade de São Paulo) ; Shah, M. A. (Medical Oncology/Solid Tumor Program. Sandra and Edward Meyer Cancer Center. Weill Cornell Medical College) ; Shen, L. (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing). Department of Gastrointestinal Oncology. Peking University Cancer Hospital and Institute) ; Kang, Y. K. (Department of Oncology. Asan Medical Center. University of Ulsan College of Medicine) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Girish, S. (Clinical Pharmacology. Genentech Research and Early Development) ; Garg, Amit (Clinical Pharmacology. Genentech Research and Early Development) ; Universitat Autònoma de Barcelona
Purpose: To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the pertuzumab regimen in these patients. [...]
2019 - 10.1007/s00280-019-03871-w
Cancer Chemotherapy and Pharmacology, Vol. 84 Núm. 3 (january 2019) , p. 539-550  
2.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A. X (Massachusetts General Hospital (Boston)) ; Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ; Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942  
3.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO open, Vol. 2 (november 2017)  

See also: similar author names
3 Ohtsu, A.
2 Ohtsu, Atsushi
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.